Objectives-To determine the association between the £2 and £4 alleles of apolipoprotein E (ApoE) and independent measures of cognitive decline and noncognitive symptomatology in late onset Alzheimer's disease. Methods-The frequency of the £2 and £4 alleles of ApoE and their association with measures of cognitive decline and noncognitive symptomatology were assessed in a population based case register study of 164 patients with late onset Alzheimer's disease from the east Lambeth and south Southwark districts of south London. Results-Analysis of a wide range of noncognitive symptoms against ApoE £4 genotype showed no significant association but a positive relation was found between ApoE £2 genotype and depressive symptomatology (P = 0.004). No relation was found between measurements of cognitive decline and the presence of the ApoE £4 allele. A trend for decreasing age at onset of 3 to 4 years in carriers of the ApoE £4 allele was found, confirming earlier studies. Conclusion-Presence of the £4 allele of ApoE is associated with an earlier age at onset but does not seem to be related to either a more severe psychopathology or a more rapid progression of the illness. The £2 allele of ApoE is associated with depressive symptomatology in late onset Alzheimer's disease.
The importance of apolipoprotein E (ApoE) as a risk factor for familial and sporadic late onset Alzheimer's disease has been the focus of several investigations.' 2 Whereas some light has been shed on the relation between the ApoE genotype and the neuropathological features seen in Alzheimer's disease,3 information on its relation with the clinical features of Alzheimer's disease is largely confined to demographic variables such as age at onset. ' The association between the psychopathology of the disease and ApoE genotype has been relatively unexplored. What studies have been done have concentrated on measures of cognitive decline and its relation with the ApoE £4 allele.4 6 Whereas, by most definitions,7 Alzheimer's disease has at its core features of cognitive decline, there is clearly a large non-cognitive component which has major implications in the treatment and placement of patients.
The clinical features and progression of Alzheimer's disease may differ according to the setting in which the patient is found"' and case series of patients with dementia often select an atypical population.' 5These findings emphasise the importance of population based cohort studies for clinicopathological and genetic correlation. However, even relatively large population studies2 4 result in few patients with Alzheimer's disease and hence there is also a need for a case register study representative of dementia subjects in the community.
Methods

PATIENTS
At the time of writing the next of kin of 200 patients from a present total of 424 on the Camberwell Case Register" 12 had consented to venepuncture and genetic testing. All patients were over 60 years of age at the onset of their illness. The case register is cumulative and was set up with the aim of identifying all persons drawn from a defined catchment area population who make contact with specialist agencies (psychiatric, geriatric, long stay care, or social services for the elderly) and are confirmed to have late life dementia. mant questionnaire'5 with additional questions from the Present behavioural examination16 and Stockton geriatric rating scale.'7 All patients were cognitively assessed at initial presentation and subsequently at yearly intervals by means of the mini mental state examination (MMSE)'8 and the Blessed dementia rating scale (BDRS). 19 Yearly cognitive decline was calculated as the difference between the initial examination and that at first yearly follow up or as the mean rate of change over a two year period if a second yearly assessment had been made. In order not to underestimate rates of decline cases were selected with MMSE > 5 at initial examination as this represented the upper range of most predicted values of yearly cognitive decline. 20 Non-cognitive variables were grouped in the register into five main categories and further subcategorised as follows: disorders of thought into persecutory and other delusions; disorders of perception into auditory, visual, and other hallucinatory phenomena plus misidentifications; disorders of mood into depressive and aggressive symptomatology; disorders of behaviour into wandering and stereotypical behaviours; and neurovegetative features into abnormalities of sleep and eating disorders. Each of the 12 subcategories was composed of five questions which were asked of the informant and the responses noted as symptom present or absent during the subject's illness. In addition, depressive features were assessed using the Cornell scale for depression in dementia.2' APOE GENOTYPES Blood samples were collected on EDTA and stored at -70°C until assayed. ApoE genotyping was carried out using one stage polymerase chain reaction followed by restriction enzyme digestion.22 Table 1 shows the frequencies of alleles among the probable, possible, and total (probable and possible cases combined) Alzheimer's disease groups compared with relatively aged controls from a previous United Kingdom study .24 Probable and possible groups did not differ significantly from each other for age at interview, age at onset, duration of illness, sex, family history of Alzheimer's disease, or for either allele. The probable Alzheimer's disease group was significantly higher than the control group for ApoE E4 allele frequency (x2 = 15 82, df = 1, P = 0 00007) and significantly lower than the control group for ApoE e2 frequency (X2 = 12-06, df = 1, P = 0-0005). Table 2 shows measurements of cognitive decline in total Alzheimer's disease cases. Possession of the ApoE e4 allele was associated with a roughly 3 year earlier age at onset (Mann-Whitney U test, P = 0 004). Analysis of the probable Alzheimer's disease group alone likewise showed a similar trend with a roughly 4 year earlier age at onset (MannWhitney U test, P = 0001). No association was found between measurements of MMSE, BDRS, or disease duration at initial interview and presence or absence of the ApoE e4 allele.
Of the 164 patients from the total Alzheimer's disease group 145 had a one year follow up (13 had died and six relatives had not responded to requests for follow up). Of these cases, 107 had an initial MMSE score greater than or equal to five points (mean initial MMSE 13-0 (SD 5-1). Thirty seven of these patients had had a second yearly follow up at the time of this study. No significant difference was found between measurements of yearly cognitive decline (mean MMSE decline 2-6 (SD.3-5) points per year and BDRS decline 1 1 (SD 2 9) points per year) for either MMSE or BDRS and the presence of the ApoE e4 or ApoE e2 alleles in the total Alzheimer's disease group adjusting for baseline measurements. Likewise, analysis of the probable Alzheimer's disease group alone failed to show a relation between either pos-session of ApoE 84 or 82 alleles with measurements of cognitive decline.
No significant association was found between the 12 non-cognitive subcategories and ApoE £4 gene dosage after Bonferroni correction. Likewise no significant association was found between 11 non-cognitive subcategories and ApoE 82 gene dosage. However, the depressive subcategory score, consisting of the aggregate score of the five composite questions pertaining to depressive symptomatology, was significantly associated with the presence of the ApoE 82 allele in the total Alzheimer's disease group (n = 9, MannWhitney U test, P = 0-004 after Bonferroni correction) and in the probable Alzheimer's disease group alone (n = 5, Mann-Whitney U test, P = 0-018 after Bonferonni correction). 
